ArticlePsychiatry investigation2025
Analysis of Antipsychotic Drug Use Patterns and Safety in Patients With Bipolar Disorder.
Article in Psychiatry investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the pattern of antipsychotic drug use and safety in patients with bipolar disorder (BD).
methodsA retrospective analysis was conducted using a convenience sampling method to collect medical records of 150 BD patients who attended our psychiatric outpatient clinic from July to December 2023. The treatment and follow-up period lasted for 12 months. Based on the use of antipsychotics during the follow-up period, patients were categorized into three subgroups: typical antipsychotics only atypical antipsychotics only, and concurrent use of both antipsychotics. Their medication use, adverse effects, and specific observation indicators including the number of antipsychotics used, the percentage of anticholinergics used, the incidence of somatic discomfort, cognitive impairment, memory loss, and decreased attention were compared.
resultsThere was no statistically significant difference between the three groups in terms of gender, age, whether they worked or not, and comorbidities (p>0.05); the difference between the three groups was statistically significant in terms of the percentage of the number of antipsychotics used and the percentage of anticholinergics used (p<0.001), and there was no statistically significant difference in terms of the percentage of other adjunctive psychotropic medications or the percentage of the use of traditional Chinese medicines (p>0.05); during the follow-up period, all three groups of patients had symptoms of somatic discomfort, cognitive impairment, memory loss, and decreased attention, but the difference in their incidence was not statistically significant (p>0.05); moreover, none of the three groups of patients had impairments of liver and kidney functions during the follow-up period.
conclusionAntipsychotics play a crucial role in treating BD patients. This study provides insights into optimizing treatment strategies by highlighting the importance of considering both safety and efficacy when prescribing antipsychotics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.